Myriad Genetics, Inc.
NASDAQ:MYGNMedical - Diagnostics & Research
+$0.14 today
- Market cap
- $530.45M
- Beta
- 1.64
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$4.27
Volume 1.26M
Average 1.81M
MYGN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Myriad Genetics, Inc.NASDAQ: MYGN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $12.5M fell 13.2% year over year, in line with the -13.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.8% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.
Context
- Depreciation & amortization amounted to 6.5% of revenue in FY2025, down 0.8 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -13.2% holds above the trailing-twelve-month pace of -13.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 53.7M USD
- Year-over-year change
- -12.3%
- 4-year CAGR
- -3.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 53.7M | -12.3% |
| FY2024 | 2024-12-31 | 61.2M | -1.1% |
| FY2023 | 2023-12-31 | 61.9M | +17.5% |
| FY2022 | 2022-12-31 | 52.7M | -16.1% |
| FY2021 | 2021-12-31 | 62.8M | — |
Depreciation & Amortization vs competitors
How MYGN compares with its peers on the latest reported figures
- MYGN's LTM Mar 2026 depreciation & amortization of $51.8M is the 4th largest of the 10 companies compared; the peer median is $24.2M.
- Its year-over-year change of -13.5% is the lowest of 9, against a peer median of -1.1%.
- Depreciation & amortization amounts to 6.2% of revenue for MYGN, versus a peer median of 7.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $202.13M | +7.0% | -2.4% | 9.6% | |
| LTM Jun 2026 | $65.8M | +87.5% | +37.6% | 2.4% | |
| LTM Jun 2026 | $65.46M | -8.0% | -0.8% | 8.5% | |
| LTM Mar 2026 | $51.8M | -13.5% | +0.6% | 6.2% | |
| LTM Sep 2026 | $39.23M | -2.3% | +3.4% | 3.1% | |
| LTM Mar 2026 | $24.2M | +0.1% | -9.6% | 7.6% | |
| LTM Jun 2026 | $20.83M | -9.4% | -6.2% | 3.7% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $12.3M | — | — | 3.1% |
| LTM Mar 2026 | $9.83M | -8.1% | +6.0% | 15.2% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $2.34M | +35.9% | -25.1% | 119.9% |
| Peer median (excluding MYGN) | $24.2M | -1.1% | -1.6% | 7.6% | |
Competitors are the stored peer set for MYGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.2M) | (112M) | (263.3M) | (127.3M) | (365.9M) |
| Depreciation & Amortization | 62.8M | 52.7M | 61.9M | 61.2M | 53.7M |
| Deferred Income Tax | (34.7M) | (31.9M) | (600K) | (300K) | (32.4M) |
| Stock-Based Compensation | 36.3M | 38.1M | 40.7M | 49.8M | 35.2M |
| Change in Working Capital | 120.8M | (83.5M) | 27M | (54.4M) | (19.3M) |
| Accounts Receivables | (8.8M) | 7.7M | 3.8M | (8.7M) | 6.2M |
| Inventory | 1.6M | (2.9M) | (1.8M) | (6.2M) | (3.2M) |
| Accounts Payables | 9.2M | (3.5M) | (3.7M) | 4.7M | (1.4M) |
| Other Working Capital | 118.8M | (84.8M) | 28.7M | (44.2M) | (20.9M) |
| Other Non-Cash Items | (139.4M) | 30.3M | 23.4M | 62.3M | 21.1M |
| Operating Cash Flow | 18.6M | (106.3M) | (110.9M) | (8.7M) | 1.8M |
| Capital Expenditures | (18M) | (45.3M) | (73.3M) | (29.7M) | (15.6M) |
| Acquisitions (Net) | 379.1M | (57.2M) | 0 | 8.8M | 0 |
| Purchases of Investments | (147.8M) | (103.2M) | 0 | 0 | 0 |
| Sales of Investments | 61.1M | 128.2M | 105.2M | 9M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 274.4M | (77.5M) | 31.9M | (11.9M) | (27.4M) |
| Debt Repayment | (226.4M) | — | 39.8M | 100K | 75.9M |
| Common Stock Issued | 0 | 0 | 117.6M | 0 | 3.3M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 75.8M | (8M) | (4.5M) | (7.5M) | (15M) |
| Financing Cash Flow | (150.6M) | (8M) | 152.9M | (7.4M) | 64.2M |
| Effect of Forex Changes | (600K) | (600K) | 600K | (1M) | 800K |
| Net Change in Cash | 141.8M | (192.4M) | 74.5M | (29M) | 39.4M |
| Free Cash Flow | 600K | (151.6M) | (184.2M) | (38.4M) | (13.8M) |
Myriad Genetics, Inc.
NASDAQ:MYGN
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.